Eli Lilly and Company
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LLY.SW | 0QCV.IL | BMY | BIIB | 0QYQ.IL | AZN | |
|---|---|---|---|---|---|---|
| Market cap | 1.05T | 539.67B | 131.21B | 37.61B | 218.56B | 293.14B |
| P/E (TTM) | 48.1 | 61.7 | 14.2 | 110.2 | 40.3 | 26.7 |
| Forward P/E | — | — | 9.6 | 15.6 | — | 16.7 |
| Price/book | 31.7 | 41.2 | 5.6 | 2.0 | 10.3 | 5.7 |
| Dividend yield | 0.49% | 4.05% | 3.93% | — | 3.81% | 1.69% |
| 1-year change | +51.63% | +33.33% | +37.66% | +62.35% | +38.91% | +12.81% |
| Today | +23.56% | +5.63% | +4.02% | +2.22% | +1.98% | +2.79% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All LLY.SW news ›Eli Lilly: Priced For Acceleration, Reporting Deceleration
Eli Lilly delivered strong Q3 results, but underlying growth slowed from 49% to 35% and price erosion deepened. Read more on LLY stock here. - Eli Lilly delivered strong Q3 results, but underlying growth slowed from 49% to 35% and price…
Lilly Surges As Its Drugs Melt Pounds. Among 16 New To Best Stock Lists
Worked nearly 18 years until 2016 as a full-time reporter/copy editor with Investor's Business Daily, a leading business news company. Contributing writer for Forbes.com for a year and a half before returning to IBD. Currently a full-time…
Celltrion unveils promising results for four-target obesity drug
Published : Nov. 4, 2026 - 14:06:28 Celltrion has unveiled promising preclinical results for its next-generation obesity drug candidate, CT-G32/SCO-940, which outperformed a leading experimental weight-loss treatment in animal testing and…
Strong Momentum Meets Stretched Valuations as Emcure Pharmaceuticals Ltd Reaches All-Time High
Strong Price Momentum and Market Outperformance On 04 Nov 2026, Emcure Pharmaceuticals Ltd’s stock surged by 8.15% in a single day, substantially outperforming the Sensex, which gained a modest 0.59%. The stock opened with a gap up of…
Celltrion Unveils Preclinical Data on Quadruple-Action Obesity Drug
Animal Study Shows Greater Weight Loss Than Triple-Action Agent FDA Filing Due in February, First Patient Dosing Targeted for Q2 Celltrion (068270.KS) has released preclinical results for an obesity drug candidate that simultaneously…
Eli Lilly Just Delivered Another Monster Quarter. But There’s More to This Story Than Weight-Loss Drugs
Eli Lilly's weight-loss drugs get all the headlines, but CEO David Ricks is betting the company's next act looks nothing like its last one. Here is what it would actually take for shares to reach $1,700 in 2027. Eli Lilly (NYSE:LLY | LLY…
Celltrion touts four-hormone obesity drug that tops triple-action rival
Celltrion claims CT-G32's four-pathway approach outperforms triple-agonists and preserves more lean mass, with FDA filing planned and first dosing eyed for Q2 2027 Celltrion said on the 4th that it presented preclinical study results for…
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award
Company selected for the Leaders in Drug Resistance Development award Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the…
Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor
Erik Flyg from Bloomberg and Sergei Starostin from Pexels via Canva Eli Lilly (LLY) hit a record high on Friday, and it’s now worth about $1.1 trillion, as much as Berkshire Hathaway. The rally came after a monster quarter. Third-quarter…
FDA Approval for BENLYSTA issued to GLAXOSMITHKLINE LLC
FDA approved SUPPL-38 label update for BENLYSTA (belimumab) BLA 761043 on 10/30/2026; no new indication or pricing detail disclosed. Plus members following GSK got this by push and email at 17:45:48 ET - 2.9s after publication. The FDA…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com248
- themarketsdaily.com108
- seekingalpha.com77
- fool.com66
- defenseworld.net61
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.